Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I study initiated for REN-001 in McArdle disease

Jan. 22, 2020

Phase I study of TAK-169 in relapsed or refractory multiple myeloma underway

Jan. 22, 2020

Signs of efficacy seen with ONCOS-102 and chemotherapy in mesothelioma trial

Jan. 22, 2020

Tepezza approved in the U.S. for thyroid eye disease

Jan. 22, 2020

TNFAIP1 is a tumor suppressor in heptocellular carcinoma

Jan. 22, 2020

Boehringer Ingelheim presents GPR142 agonists

Jan. 22, 2020

DFH Therapeutics and HHS describe betulinic acid derivatives for HIV infection

Jan. 22, 2020

AlzeCure Pharma discloses new Trk-A and Trk-B modulators

Jan. 22, 2020

Yale University divulges let-7 microRNA-activating compounds for endometriosis

Jan. 22, 2020

Catalent patents decorin-containing products for cancer

Jan. 22, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...